Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Dachs1on Feb 20, 2016 12:38pm
230 Views
Post# 24577957

RE:Biotech-Roundup: Sirona Biochem, Paion, Atossa Genetics, Bio

RE:Biotech-Roundup: Sirona Biochem, Paion, Atossa Genetics, Biogoogle translater German -> English:

After a streaky race of the year many eyes have been concentrating on the investor risk, but also often so lucrative biotech sector again. Values such as Sirona Biochem (WKN: A0RM6R) Paion (WKN: A0B65S) or Atossa Genetics (WKN: A1J79S) are more than ever in the focus. The Biodel share (WKN: A1JZU5) is now on the radar.
 
Since our first report on Sirona Biochem (WKN: A0RM6R) from 2014. A lot has happened. The highly innovative technology platform of Canadians arouses more and more interest of large companies in the cosmetics and pharmaceutical industry. At the time of our initial presentation a Sirona shares only cost about 8 euro cents, now it is trading at almost 14 cents.
 
In recent days, pulling sales price at Sirona again noticeably. With a current Video Post Sirona addressed specifically German speaking investors. The prospect of timely royalties should keep the interest in the stock high. Also rumored repeatedly of an impending partnership with one billion consolidated. Rapid price gains could be limited by any outstanding stock options initially, in the medium term the Sirona paper should, however, take on new highs in attack.

https://www.sharedeals.de/2016/02/biotech-roundup-sirona-biochem-paion-atossa-genetics-biodel/
Bullboard Posts